TNGX · Insider Trading
Tango Therapeutics, Inc.
Every open-market purchase and sale reported by TNGX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Adam Crystal | President, R&D | MIXED | — | −$520.40K |
| 2026-09-24 | Jessica Newcomb | Principal Accounting Officer | Sell | −8,200 | −$198.61K |
| 2026-09-03 | Adam Crystal | President, R&D | MIXED | — | −$463.51K |
| 2026-08-05 | Adam Crystal | President, R&D | MIXED | — | −$595.12K |
| 2026-07-02 | Adam Crystal | President, R&D | MIXED | — | −$658.51K |
| 2026-06-23 | Robert Azelby | Director | A | +5,740 | — |
| 2026-06-08 | Lesley Ann Calhoun | Director | A | +4,000 | — |
| 2026-06-08 | Mace Rothenberg | Director | A | +4,000 | — |
| 2026-06-08 | John B Ketchum | Director | A | +4,000 | — |
| 2026-06-08 | Sung Lee | Director | A | +570 | — |
| 2026-06-03 | Adam Crystal | President, R&D | MIXED | — | −$477.17K |
| 2026-05-05 | Matthew Gall | Chief Financial Officer | A | +40,000 | — |
| 2026-05-05 | Adam Crystal | President, R&D | MIXED | — | −$432.70K |
| 2026-05-01 | Sung Lee | Director | A | +12,300 | — |
| 2026-04-16 | Adam Crystal | President, R&D | MIXED | — | −$761.51K |
| 2026-04-02 | Adam Crystal | President, R&D | MIXED | — | −$432.08K |
| 2026-03-27 | Adam Crystal | President, R&D | MIXED | — | −$178.92K |
| 2026-03-09 | Adam Crystal | President, R&D | Sell | −20,251 | −$303.76K |
| 2026-02-27 | Adam Crystal | President, R&D | Sell | −54,345 | −$694.21K |
| 2026-02-04 | Barbara Weber | Director, Executive Chair | MIXED | +7,003 | −$374.29K |
| 2026-02-04 | Adam Crystal | President, R&D | MIXED | +29,008 | −$226.30K |
| 2026-02-04 | Daniella Beckman | Chief Financial Officer | MIXED | +34,013 | −$126.53K |
| 2026-01-12 | Malte Peters | President & CEO | A | +350,000 | — |
| 2026-01-06 | Sung Lee | Director | A | +10,000 | — |
| 2025-11-04 | Malte Peters | Director | A | +150,000 deriv. | — |
| 2025-10-27 | TRV GP IV, LLC | 10%+ Owner | Sell | −1,432,203 | −$14.54M |
| 2025-09-29 | TRV GP IV, LLC | 10%+ Owner | Sell | −1,500,000 | −$12.03M |
| 2025-09-17 | Third Rock Ventures IV, L.P. | 10%+ Owner | Sell | −1,090,623 | −$7.68M |
| 2025-09-09 | TRV GP IV, LLC | 10%+ Owner | Sell | −2,188,095 | −$15.33M |
| 2025-08-26 | TRV GP IV, LLC | 10%+ Owner | Sell | −906,582 | −$6.35M |
| 2025-08-21 | TRV GP IV, LLC | 10%+ Owner | Sell | −3,300,000 | −$23.14M |
| 2025-06-09 | John B Ketchum | Director | A | +6,250 | — |
| 2025-06-09 | Lesley Ann Calhoun | Director | A | +6,250 | — |
| 2025-06-09 | Malte Peters | Director | A | +6,250 | — |
| 2025-06-09 | Alexis Borisy | Director | A | +6,250 | — |
| 2025-06-09 | Mace Rothenberg | Director | A | +6,250 | — |
| 2025-02-06 | Adam Crystal | See Remarks | Sell | −14,283 | −$43.87K |
| 2025-02-06 | Barbara Weber | Chief Executive Officer | Sell | −18,791 | −$57.71K |
| 2025-02-06 | Douglas Barry | General Counsel | Sell | −5,330 | −$16.37K |
| 2025-02-06 | Daniella Beckman | Chief Financial Officer | Sell | −8,232 | −$25.28K |
| 2025-02-05 | Daniella Beckman | Chief Financial Officer | A | +26,119 | — |
| 2025-02-05 | Douglas Barry | General Counsel | A | +27,363 | — |
| 2025-02-05 | Barbara Weber | Chief Executive Officer | A | +105,875 | — |
| 2025-02-05 | Adam Crystal | See Remarks | A | +53,015 | — |
| 2024-11-18 | Mace Rothenberg | Director | Buy | +20,000 | +$74.00K |
| 2024-11-08 | EcoR1 Capital, LLC | 10%+ Owner | Sell | −2,700,000 | −$8.44M |
| 2024-11-07 | Boxer Capital Management, LLC | — | Sell | −6,160,000 | −$19.34M |
| 2024-10-28 | Aaron I. Davis | — | Sell | −1,266,000 | −$8.70M |
| 2024-10-23 | Boxer Capital Management, LLC | — | Sell | −1,750,000 | −$12.20M |
| 2024-09-17 | TRV GP IV, LLC | 10%+ Owner | Sell | −202,200 | −$2.13M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Third Rock Ventures IV, L.P. | 10%+ Owner | 14,363,975 | $388.26M |
| TRV GP IV, LLC | 10%+ Owner | 13,386,574 | $361.84M |
| EcoR1 Capital, LLC | 10%+ Owner | 11,836,178 | $319.93M |
| Boxer Capital Management, LLC | — | 7,432,435 | $200.90M |
| Aaron I. Davis | Director | 6,799,435 | $183.79M |
| Barbara Weber | Director, Executive Chair | 1,629,587 | $44.05M |
| Malte Peters | President & CEO | 367,500 | $9.93M |
| Daniella Beckman | Chief Financial Officer | 184,410 | $4.98M |
| Adam Crystal | President, R&D | 115,743 | $3.13M |
| Jessica Newcomb | Principal Accounting Officer | 66,621 | $1.80M |
| Douglas Barry | General Counsel | 66,014 | $1.78M |
| Mace Rothenberg | Director | 41,500 | $1.12M |
| Matthew Gall | Chief Financial Officer | 40,000 | $1.08M |
| John B Ketchum | Director | 24,937 | $674.05K |
| Sung Lee | Director | 22,870 | $618.18K |
| Alexis Borisy | Director | 17,500 | $473.02K |
| Lesley Ann Calhoun | Director | 16,500 | $446.00K |
| Robert Azelby | Director | 5,740 | $155.15K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TNGX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.